Patents by Inventor Aimo Kannt

Aimo Kannt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
    Patent number: 11352405
    Abstract: The present invention relates to the medical use of specific GLP-1/glucagon receptor agonists in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), more particularly non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH) and/or NAFLD-associated liver fibrosis.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: June 7, 2022
    Assignee: SANOFI
    Inventors: Aimo Kannt, Maximilian Bielohuby, Ralf Elvert, Michael Wagner, Martin Bossart, Torsten Haack, Stephanie Keil, Werner Seiz
  • GLP-1/GLUCAGON RECEPTOR AGONISTS IN THE TREATMENT OF FATTY LIVER DISEASE AND STEATOHEPATITIS
    Publication number: 20200216510
    Abstract: The present invention relates to the medical use of specific GLP-1/glucagon receptor agonists in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), more particularly non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH) and/or NAFLD-associated liver fibrosis.
    Type: Application
    Filed: August 8, 2018
    Publication date: July 9, 2020
    Inventors: Aimo KANNT, Maximilian BIELOHUBY, Ralf ELVERT, Michael WAGNER, Martin BOSSART, Torsten HAACK, Stephanie KEIL, Werner SEIZ
  • A NOVEL SOLUBLE BIOMARKER FOR INSULIN RESISTANCE
    Publication number: 20170082643
    Abstract: The present invention relates to a novel soluble biomarker for insulin resistance: 1-methyl nicotinamide (MNA). The invention relates to methods of determining the degree of insulin resistance in a patient. The invention further relates to methods for determining whether a subject with insulin resistance or type 2 diabetes will benefit from a treatment with an inhibitor of nicotinamide-N-methyltransferase (NNMT) or whether a subject responds to a therapeutic treatment with an NNMT inhibitor.
    Type: Application
    Filed: June 11, 2015
    Publication date: March 23, 2017
    Inventors: Aimo Kannt, Anja Pfenninger, Matthias Blüher
  • Substituted 6-(4-hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
    Patent number: 9133181
    Abstract: The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R1, R2, R3, R4, R5 and R6 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: September 15, 2015
    Assignee: SANOFI
    Inventors: Stephanie Hachtel, Christian Schoenau, Matthias Loehn, Oliver Plettenburg, Stefania Pfeiffer-Marek, Alexander Schiffer, Holger Gaul, Aimo Kannt, Juergen Dedio, Angela Dudda
  • SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20150133432
    Abstract: The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R1, R2, R3, R4, R5 and R6 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 14, 2015
    Inventors: Stephanie HACHTEL, Christian SCHOENAU, Matthias LOEHN, Oliver PLETTENBURG, Stefania PFEIFFER-MAREK, Alexander SCHIFFER, Holger GAUL, Aimo KANNT, Juergen DEDIO, Angela DUDDA
  • 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
    Patent number: 8846712
    Abstract: The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R1, R2, R3, R4 and R5 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: September 30, 2014
    Assignee: Sanofi
    Inventors: Matthias Loehn, Maria Mendez-Perez, Stefania Pfeiffer-Marek, Aimo Kannt, Guillaume Begis, Olivier Duclos, Federic Jeannot
  • Isoquinoline derivatives
    Patent number: 8722671
    Abstract: The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: May 13, 2014
    Assignee: Sanofi
    Inventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Kurt Ritter, Matthias Loehn, Yuri Ivashchenko, Peter Monecke, Matthias Dreyer, Aimo Kannt
  • Cycloalkylamine substituted isoquinoline derivatives
    Patent number: 8710228
    Abstract: The invention relates to 6-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: April 29, 2014
    Assignee: Sanofi
    Inventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Matthias Löhn, Peter Monecke, Alexander Schiffer, Aimo Kannt, Markus Kohlmann
  • 6-(4-hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
    Patent number: 8686150
    Abstract: The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R1, R2, R3, R4, R5, R6 and R7 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: April 1, 2014
    Assignee: Sanofi
    Inventors: Stephanie Hachtel, Oliver Plettenburg, Christian Schoenau, Matthias Loehn, Stefania Pfeiffer-Marek, Maria Mendez-Perez, Aimo Kannt, Juergen Dedio, Markus Kohlmann, Alexander Schiffer, Guillaume Begis, Olivier Duclos, Frederic Jeannot
  • Isoquinoline derivatives
    Patent number: 8501736
    Abstract: The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: August 6, 2013
    Assignee: Sanofi
    Inventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Kurt Ritter, Matthias Loehn, Yuri Ivashchenko, Peter Monecke, Matthias Dreyer, Aimo Kannt
  • METHOD FOR IDENTIFYING A COMPOUND HAVING AN ANTIARRHYTHMIC EFFECT AS WELL AS USES RELATING THERETO
    Publication number: 20130123143
    Abstract: The present invention relates to a method of identifying a compound having an antiarrhythmic effect and to a use of adenosine-diphospho-ribose cyclase (cardiac ADPRC) for the identification of a compound having said effect.
    Type: Application
    Filed: July 25, 2011
    Publication date: May 16, 2013
    Applicant: SANOFI
    Inventors: Aimo Kannt, Dieter Kadereit, Heinz Goegelein
  • 6-(4-HYDROXY-PHENYL)-3-STYRYL-1H-PYRAZOLO[3,4-b]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20130065894
    Abstract: The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R1, R2, R3, R4 and R5 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: September 12, 2011
    Publication date: March 14, 2013
    Applicant: SANOFI
    Inventors: Matthias LOEHN, Maria MENDEZ-PEREZ, Stefania PFEIFFER-MAREK, Aimo KANNT, Guillaume BEGIS, Olivier DUCLOS, Federic JEANNOT
  • CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES
    Publication number: 20110251226
    Abstract: The invention relates to 6-cyclohexylamine-substituted isoquinolone derivatives of the formula (I) or isoquinoline derivatives of the formula (I?) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Application
    Filed: June 15, 2011
    Publication date: October 13, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Kurt Ritter, Matthias Loehn, Yuri Ivashchenko, Peter Monecke, Matthias Dreyer, Aimo Kannt
  • ISOQUINOLINE DERIVATIVES
    Publication number: 20110245248
    Abstract: The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Application
    Filed: June 15, 2011
    Publication date: October 6, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Kurt Ritter, Matthias Loehn, Yuri Ivashchenko, Peter Monecke, Matthias Dreyer, Aimo Kannt
  • Use of IRS-polypeptides for identifying of pharmaceutically active compounds
    Patent number: 7732151
    Abstract: An assay for determining the ability of an enzyme, functional fragment, or functional derivative thereof to modify the phosphorylation status of a biotinylated polypeptide.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: June 8, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Norbert Tennagels, Aimo Kannt, Harald Thuering
  • Cycloalkylamine substituted isoquinoline derivatives
    Publication number: 20100081671
    Abstract: The invention relates to 6-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Application
    Filed: June 18, 2009
    Publication date: April 1, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Oliver PLETTENBURG, Armin HOFMEISTER, Dieter KADEREIT, Stefan PEUKERT, Sven RUF, Matthias LÖHN, Peter MONECKE, Alexander SCHIFFER, Aimo KANNT, Markus KOHLMANN
  • Isoquinoline Derivatives
    Publication number: 20090088429
    Abstract: The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Application
    Filed: December 20, 2007
    Publication date: April 2, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Oliver PLETTENBURG, Armin HOFMEISTER, Dieter KADEREIT, Stefan PEUKERT, Sven RUF, Kurt RITTER, Matthias LOEHN, Yuri IVASHCHENKO, Peter MONECKE, Matthias DREYER, Aimo KANNT
  • Use of IRS-polypeptides for identifying of pharmaceutically active compounds
    Publication number: 20080020399
    Abstract: An assay for determining the ability of an enzyme, functional fragment, or functional derivative thereof to modify the phosphorylation status of a biotinylated polypeptide.
    Type: Application
    Filed: May 19, 2004
    Publication date: January 24, 2008
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Norbert Tennagels, Aimo Kannt, Harald Thuering
  • High-throughput-assay with high sensitivity for measuring of the activity of ?-adrenergic receptor kinase and for determining the impact of test substances on such activity
    Patent number: 7279286
    Abstract: The present invention relates to an assay for determining the activity of a G-Protein-Coupled Receptor specific protein kinase by means of an amplified luminescent proximity homo homogenous assay.
    Type: Grant
    Filed: August 31, 2004
    Date of Patent: October 9, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Aimo Kannt, Antje Pommereau, Harald Thuering, Jochen Huber, Martin Oppermann
  • High-throughput-assay with high sensitivity for measuring of the activity of beta-adrenergic receptor kinase and for determining the impact of test substances on such activity
    Publication number: 20050059098
    Abstract: The invention refers to an assay for determining the activity of a G-Protein-Coupled Receptor specific protein kinase by means of an amplified luminescent proximity homogenous assay.
    Type: Application
    Filed: August 31, 2004
    Publication date: March 17, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Aimo Kannt, Antje Pommereau, Harald Thuering, Jochen Huber, Martin Oppermann